A
Apogee Therapeutics
Develops advanced biologics for treating inflammatory and immune diseases like atopic dermatitis and asthma
About Apogee Therapeutics
Apogee Therapeutics is a biotechnology startup that specializes in developing unique biological treatments for diseases with high unmet needs, such as atopic dermatitis (a type of skin inflammation), chronic obstructive pulmonary disease (a type of lung disease), and other inflammatory and immune diseases. The company aims to improve the current standard of care for these diseases, believing that patients deserve the best possible treatment.
Apogee's business model revolves around the creation and development of antibody therapeutics, which are drugs that can stimulate the body's immune system to fight diseases. These drugs target well-established biological drivers and development pathways, with a primary focus on improving treatments for atopic dermatitis and chronic obstructive pulmonary disease.
The company's revenue is likely generated through the sale of these therapeutics to healthcare providers and patients. It may also earn income from partnerships with other biotech firms or pharmaceutical companies, and potentially from grants or investments for research and development.
Apogee's team consists of experienced drug developers and operators who are motivated by the goal of providing better treatment options for people living with inflammatory and immune diseases. The company places a strong emphasis on creating a psychologically safe environment where everyone feels comfortable sharing ideas, reflecting its people-first philosophy.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2023
Open roles
Apogee Therapeutics in the Waltham ecosystem
The Apogee Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Fairmount Funds Management- VPVenrock Healthcare Capital Partners
Fidelity Investments
RTW Investments
RA Capital Management
Wellington Management
OrbiMed
Deep Track Capital- PFPerceptive Xontogeny Venture Fund
Series B and later4 investors entered at this stage
Paragon Therapeutics- PMPlatinum Investment Management
Great Point Partners
Blackstone
Source: Dealroom Talent Intelligence.
Patents
11 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Apogee Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Alaunos buys Velaris as ex-Apogee team joins Paragon after $10.9B AbbVie deal
AbbVie acquires Apogee for $10.9B (September 2026)
